Correlation between serum carbohydrate antigen 19-9 levels and computed tomography severity score in patients with nontuberculous mycobacterial pulmonary disease by 강영애 et al.
1
Vol.:(0123456789)
Scientific Reports |         (2021) 11:2777  | https://doi.org/10.1038/s41598-021-82363-5
www.nature.com/scientificreports
Correlation between serum 
carbohydrate antigen 19‑9 levels 
and computed tomography 
severity score in patients 
with nontuberculous mycobacterial 
pulmonary disease
Kangjoon Kim1, Seung Hyun Yong1, Su Hwan Lee1, Sang Hoon Lee1, Ah Young Leem1, 
Song Yee Kim1, Kyungsoo Chung1, Eun Young Kim1, Ji Ye Jung1, Moo Suk Park1, 
Young Sam Kim1, Hye‑Jeong Lee2* & Young Ae Kang1,3*
There is no validated clinical biomarker for disease severity or treatment response for nontuberculous 
mycobacterial pulmonary disease (NTM‑PD). We investigated the correlation between elevated 
serum carbohydrate antigen (CA) 19‑9 levels and NTM‑PD disease activity, defined using an imaging 
severity score based on chest computed tomography (CT). We retrospectively examined 79 patients 
with NTM‑PD who underwent serum CA19‑9 level assessments and chest CT less than 1 month apart. 
NTM‑PD severity was rated using a CT‑based scoring system. The correlation between the CT score 
and serum CA19‑9 levels was evaluated. Chest CT revealed nodular bronchiectasis without cavitation 
in most patients (78.5%). Serum CA19‑9 levels were elevated in 19 (24%) patients. Serum CA19‑9 
levels were positively correlated with the total CT score and bronchiectasis, bronchiolitis, cavity, 
and consolidation subscores. Partial correlation analysis revealed a significant positive correlation 
between serum CA19‑9 levels and CT scores for total score and bronchiectasis, bronchiolitis, 
cavitation, and consolidation subscores after controlling for age, sex, and BMI. Serum CA19‑9 levels 
were positively correlated with the CT severity score for NTM‑PD. Serum CA19‑9 may be useful in 
evaluating disease activity or therapeutic response in patients with NTM‑PD.
The incidence of nontuberculous mycobacterial pulmonary disease (NTM-PD) and its associated disease burden 
have increased  worldwide1. This is supposedly due to multiple etiologies including  environmental2, bacterial, 
and host factors such as increased life  expectancy1, a higher prevalence of immunocompromised conditions 
(e.g., immunosuppressive therapy, organ transplantation, chemotherapy)3, and an increase in the number of 
patients with comorbidities such as pre-existing lung disease, like chronic obstructive pulmonary  disease4, cystic 
 fibrosis5, or lung  cancer3,4.
It is well-known that the diagnosis of NTM-PD itself does not always require initiation of treatment. Not all 
patients with NTM-PD progress to severe  disease6, and the antimicrobial treatment of NTM-PD is frequently 
accompanied by adverse  effects7. Therefore, it is essential to devise effective measures for the evaluation of 
NTM-PD disease activity to facilitate the assessment of disease progression and provide patients with timely 
and appropriate medical treatment.
The disease activity of NTM-PD is currently evaluated by the clinician, based on a comprehensive review of 
clinical symptoms, trends on chest imaging over time, or microbiologic investigations (e.g., sputum acid-fast 
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bacillus smears and mycobacterial cultures)8. The decision to initiate treatment for NTM-PD is based on this 
assumption of disease activity or future possibility of disease progression, and potential adverse effects of 
treatment.
The following obstacles are to be considered while measuring disease activity: (1) the clinical signs are not 
disease-specific; (2) the time-trend pattern of chest imaging require months of follow-up and cannot reflect the 
disease activity of NTM-PD at a given point in time; (3) chest imaging is not always disease-specific, although 
some imaging features are known to be specific for NTM-PD9; and (4) microbiologic tests can evaluate the 
microbiological burden using smear positivity or culture positivity, but are relatively poor indicators with a crude 
scale, and the quality of the sputum specimen can affect test  results10.
Consequently, there is dire need for a simple biomarker that reflects the disease activity of NTM-PD. Few 
studies have reported on the hematological biomarkers of NTM-PD, including IgA antibodies against glyco-
peptidolipids (GPL)11, serum Krebs von den Lungen-6 (KL-6)12, and carbohydrate antigen 19-9 (CA19-9)13,14.
We focused on a previous study, which suggested a correlation between active NTM-PD and serum CA19-9 
 levels13. In that study, patients with NTM-PD exhibited elevated serum CA19-9 levels, which plummeted signifi-
cantly after treatment for NTM-PD. However, the previous study did not investigate the quantitative correlation 
between the disease activity and serum CA19-9 levels, which may be a useful biomarker.
Therefore, we aimed to further investigate the correlation between elevated serum CA19-9 levels and NTM-
PD disease activity, which was defined using an imaging severity score based on chest computed tomography 
(CT).
Methods
Participants. This retrospective study examined patients with NTM-PD who visited Severance Hospital, a 
university-affiliated tertiary referral hospital in South Korea, between January 2005 and December 2019.
All procedures performed in studies involving human participants were in accordance with the ethical stand-
ards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its 
later amendments or comparable ethical standards. The study was carried out under the permission of the Ethics 
Review Committee of Severance Hospital (IRB No. 4-2020-1103), and the need for informed consent was waived 
by the Committee because of the retrospective nature of this study.
The diagnosis of NTM-PD was based on the American Thoracic Society/Infectious Diseases Society of Amer-
ica (ATS/IDSA) diagnostic  criteria15. We excluded patients with comorbidities that could independently cause 
elevated serum CA19-9 levels from 1823 patients with NTM-PD. These comorbidities included stomach  cancer16, 
colon  cancer17, pancreatobiliary  cancer18,19, lung  cancer20, thyroid  cancer21, benign hepatobiliary  diseases22,23, 
 thyroiditis24, and ovarian  cysts25,26. The inclusion criteria were as follows: patients who underwent assessments 
for serum CA19-9 levels and chest CT scanning with an interval of less than 30 days between the two examina-
tions and participants who underwent serum CA19-9 assessment in the time period between 1 month before 
the diagnosis and the initiation of NTM-PD treatment, which was considered as the active disease period of 
NTM-PD. We selected 79 patients for the final analysis, based on the above-mentioned eligibility criteria (Fig. 1). 
Because of the small number of participants, we additionally explored the data of patients with an extended time 
interval between chest CT acquisition and serum CA19-9 assessment up to 180 days, which accounted for an 
additional 17 participants. We performed supplementary analysis including those 17 additional participants.
Data collection and measurement. We collected the patients’ demographic information, comorbidities, 
past medical history, symptom profile and progression of NTM, and treatment from their electronic medical 
records. The radiologic patterns of NTM-PD were categorized into the fibrocavitary (FC) type, nodular bron-
chiectatic (NB) type without cavitation, or NB type with cavitation. The NB form was characterized by bron-
chiectasis with multiple centrilobular nodules, and the FC form was defined by the presence of a FC lesion on 
chest  CT27.
Serum CA19-9 levels were measured with the cobas 8000 modular analyzer (Roche Diagnostics GmbH, 
Mannheim, Germany) using the electrochemiluminescence immunoassay technique. The normal range was set 
at < 34 U/mL according to the manufacturer’s instructions.
CT image evaluation. Chest CT images were obtained using 64-detector CT scanners (Discovery CT750 
HD, GE Healthcare, Chicago, IL; Somatom Sensation 64, Siemens Healthineers, Erlangen, Germany) and a 
second-generation dual-source scanner (Somatom Definition Flash; Siemens Healthineers). According to the 
purpose of the CT scans (e.g., evaluating active hemoptysis or suspected pleural disease, workup for malignancy, 
ruling out pulmonary thromboembolism, etc.), iodinated contrast agents were used for 22 patients (27.8%, 
22/79), and other patients (72.2%, 57/79) underwent non-contrast enhanced CT.
Iodinated contrast agents were used with an intravenous injection of 60 mL of contrast material (Iomeron 
300, 400 mg I/mL; Bracco Imaging, Milan, Italy) into the antecubital vein at a flow rate of 4 mL/s following by 
a 20-mL saline chaser at a rate of 4 mL/s, triggering the scan from the main pulmonary artery. All scans were 
performed from the level of the supraclavicular fossae to the adrenal glands under an inspiratory breath-hold 
with following scanning parameters: tube voltage of 120 kVp, average tube current of 300 mA, average pitch 
of 0.9, and volume CT dose index less than 6.0 mGy. After scanning, axial images were reconstructed at a slice 
thickness of 1 mm and slice increment of 1 mm with a medium-smooth convolution kernel.
We adopted the following NTM-PD CT scoring system described by a previous  study28 to evaluate the sever-
ity of NTM-PD. Bronchiectasis was considered to be present if the bronchial lumen diameter was greater than 
that of the adjacent pulmonary artery without tapering of the bronchial lumen diameter. Mucus plugging was 
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considered to be present if a broad linear or branching attenuating lesion was observed within a proximal airway 
(lobar, segmental, or subsegmental bronchus) associated with airway dilatation.
Cellular bronchiolitis was defined as the presence of centrilobular small nodules (10 mm in diameter) and 
branching nodular structures (i.e., tree-in-bud sign) on the CT scans.
The presence of other abnormalities, including cavitations; nodules (10–30 mm in diameter); and lobular 
(consolidation measuring 10–20 mm in diameter with a polygonal shape), peribronchial, or segmental consoli-
dation, was also recorded. A total CT score of 30 was allocated to determine the overall extent of lung lesions 
in each patient.
Two independent readers (one radiologist and one pulmonologist) evaluated the chest CT scans according 
to the scoring guidelines without being provided any clinical information about NTM-PD severity and CA19-9 
levels.
Statistical analysis. Descriptive variables were summarized using medians, interquartile ranges, and pro-
portions. These variables were compared based on serum CA19-9 levels (normal or elevated) using the chi-
squared test/Fisher’s exact test or the Mann–Whitney U test.
We calculated the interobserver agreement with respect to the extent and severity of bronchiectasis, cellular 
bronchiolitis, cavities, nodules, and consolidation using the intraclass correlation coefficient (ICC) because each 
observer evaluated the CT scans independently. The ICC was calculated based on a two-way random-effects 
model. The observer was allocated to the fixed-effect category, and the patient to the random-effect category. 
The ICC was considered to show poor agreement if its value was less than 0.5, moderate agreement if between 
0.5 and 0.75, good agreement if between 0.75 and 0.9, and excellent agreement if greater than 0.9029.
The correlation between serum CA19-9 levels and the CT score for NTM-PD was analyzed using Spearman’s 
correlation coefficient and Spearman’s partial correlation coefficient, controlling for variables such as age, sex, 
and body mass index (BMI) for the latter test.
A P-value < 0.05 was considered significant for all analyses. Data analysis was performed using SPSS version 
25 (IBM, Armonk, NY) and R (version 3.6.3; R Foundation for Statistical Computing, Vienna, Austria).
Results
Clinical characteristics. Of the 79 patients, 60 were women and 19 were men; the median age was 63 years 
(57–69  years). Twenty-three patients (29.1%) had a history of pulmonary tuberculosis and twelve patients 
(15.2%) had a history of diabetes mellitus. Expectoration of sputum (55.7%) and cough (44.3%) were the most 
common symptoms. Mycobacterium avium complex (MAC) was the most common pathogen (68.4%; M. avium 
Figure 1.  Selection process of the study population. NTM-PD nontuberculous mycobacterial pulmonary 
disease, CA carbohydrate antigen, CT computed tomography.
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45.6%, M. intracellulare 22.8%, both 6.3%) and most patients (78.5%) presented with the NB type without cavita-
tions on chest CT.
A clinician recommended antimicrobial treatment for NTM-PD in 37 of 79 (46.8%) patients during the 
follow-up period, and 6 patients refused treatment. Thus, only 31 (39.2%) patients received antimicrobial treat-
ment. There was no significant difference in clinical characteristics such as sex, age, BMI, symptoms, NTM 
species, or treatment initiation between the groups of patients with and without elevated serum CA19-9. The 
proportion of patients with the FC type of NTM-PD seemed to be higher in the elevated CA19-9 group, but this 
was not significant (Table 1).
Interobserver agreement. We calculated the ICC for each subcategory of the CT score and the total score 
to evaluate the interobserver agreement for CT scoring for NTM-PD severity.
The ICC for the total score exhibited good agreement (0.87, 95% CI 0.76–0.93). The ICC for the “cavitation” 
score showed good agreement (0.81, 95% CI 0.72–0.88), those for “bronchiectasis” and “cellular bronchiolitis” 
showed moderate agreement (ICC 0.73, 0.51, respectively), and those for “nodules” and “consolidation” showed 
poor agreement (ICC 0.26 and 0.27, respectively) (Table 2).
Correlation between NTM‑PD CT score and serum CA19‑9 level. We divided and compared the 
participants according to their serum CA19-9 levels (normal or elevated). Those with elevated serum CA19-9 
had significantly higher total CT scores and bronchiectasis and cavitation subscores (P < 0.05) (Table 3).
Correlation analysis revealed significant positive correlations between serum CA19-9 levels and NTM-PD 
CT scores (total score and bronchiectasis, bronchiolitis, cavity, and consolidation subscores) and a negative 
correlation between the total score and BMI (Table 4, Fig. 2). Age and BMI were not correlated with the serum 
CA19-9 level (Table 4).
Table 1.  Clinical characteristics of patients with pulmonary nontuberculous mycobacterial disease according 
to the serum CA19-9 level. Values are expressed as numbers (%) or medians (1Q–3Q). CA carbohydrate 
antigen, BMI body mass index, HTN hypertension, DM diabetes mellitus, COPD chronic obstructive 
pulmonary disease, CKD chronic kidney disease, MAC Mycobacterium avium complex, FC fibrocavitary, NB 
nodular bronchiectatic.
Total Normal CA19-9 Elevated CA19-9
P-value(N = 79) (N = 60) (N = 19)
Sex, female 60 (75.9%) 45 (75.0%) 15 (78.9%) 0.494
Age, years 63 (56–68) 61 (55–68) 64 (60–72) 0.092
BMI 20.4 (18.4–22.7) 20.4 (18.4–21.9) 20.4 (17.4–23.0) 0.991
Smoker, current or former 16 (20.3%) 13 (21.7%) 3 (15.8%) 0.423
Past history
Pulmonary TB 23 (29.1%) 19 (31.7%) 4 (21.1%) 0.550
HTN 21 (26.6%) 14 (23.3%) 7 (36.8%) 0.338
DM 12 (15.2%) 9 (15.0%) 3 (15.8%) 0.594
COPD 4 (5.1%) 2 (3.3%) 2 (10.5%) 0.243
CKD 3 (3.8%) 2 (3.3%) 1 (5.3%) 0.567
Symptom
Cough 35 (44.3%) 26 (43.3%) 9 (47.4%) 0.965
Sputum 44 (55.7%) 34 (56.7%) 10 (52.6%) 0.965
Dyspnea 11 (14.9%) 9 (15.0%) 2 (10.5%) 0.476
Hemoptysis 18 (22.8%) 11 (18.3%) 7 (36.8%) 0.089
Fever 3 (3.8%) 3 (5.0%) 0 (0.0%) 0.433
Weakness 4 (5.1%) 3 (5.0%) 1 (5.3%) 0.675
Weight loss 5 (6.3%) 4 (6.7%) 1 (5.3%) 0.653
Species 0.480
MAC 54 (68.4%) 39 (65.0%) 15 (78.9%)
M. abscessus 17 (21.5%) 13 (25.0%) 2 (10.5%)
MAC + M. abscessus 6 (7.6%) 6 (6.7%) 2 (10.5%)
Others 2 (2.5%) 2 (3.3%) 0 (0.0%)
Treatment recommendation 37 (46.8%) 25 (41.7%) 12 (63.2%) 0.120
Radiologic type 0.077
FC type 4 (5.1%) 1 (1.7%) 3 (15.8%)
NB type with cavitation 13 (16.5%) 10 (16.7%) 3 (15.8%)
NB type without cavitation 62 (78.5%) 49 (81.7%) 13 (68.4%)
CA 19-9 (U/mL) 15.1 (9.2–33.7) 12.9 (6.5–16.3) 67.6 (54.5–108.0) 0.000
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Partial correlation analysis revealed a significant positive correlation between the serum CA19-9 level and 
NTM-PD CT subscores for bronchiectasis, bronchiolitis, cavity, consolidation, and the total score, after control-
ling for age, sex, and BMI (Table 5).
In the supplementary analysis including additional 17 participants, the positive correlation between serum 
CA19-9 levels and NTM-PD CT score was still statistically significant (total score and bronchiolitis, cavity, and 
consolidation subscores; Table S2, Figure S1), and partial correlation analysis also revealed a significant positive 
correlation between serum CA19-9 levels and NTM-PD CT scores (total score and bronchiectasis, bronchiolitis, 
cavity, and consolidation subscores) after controlling for age, sex, and BMI (Table S3).
Discussion
This study sought to conduct a detailed investigation on the correlation between an increase in serum CA19-9 
levels and NTM-PD disease activity, which was defined by the CT severity score.
In this study, the serum CA19-9 level was significantly correlated with the chest CT severity score in patients 
with NTM-PD after adjusting for age, sex, and BMI. Considering the wide range of serum CA19-9 levels (within 
Table 2.  ICC for each pattern of lung abnormality. ICC intraclass correlation, CI confidence interval, CT 
computed tomography.
Pattern ICC 95% CI
Bronchiectasis 0.73 0.60–0.82




Total CT score 0.87 0.76–0.93
Table 3.  CT scores of patients with pulmonary nontuberculous mycobacterial disease, according to the serum 







(N = 19) P-value
Total (30 points) 7.8 (6.0–10.5) 12.5 (9.5–14.0) 0.001
Bronchiectasis (9 points) 3.0 (2.0–4.0) 4.0 (3.0–4.5) 0.031
Cellular bronchiolitis (6 points) 2.5 (2.0–4.0) 3.5 (2.5–5.0) 0.099
Cavitation (9 points) 0.0 (0.0–0.0) 2.5 (0.0–4.0) 0.021
Nodules (3 points) 0.5 (0.5–1.5) 0.5 (0.5–1.0) 0.318
Consolidation (3 points) 1.0 (0.5–1.5) 1.5 (1.0–1.5) 0.096
Table 4.  Result of correlation analysis using Spearman’s correlation coefficient. BMI body mass index, CA 
carbohydrate antigen. *Level of significance is 0.05, **Level of significance is 0.01. a Categories of the computed 
tomography scoring system.




BMI − 0.080 1
Bronchiec-
tasisa 0.244* − 0.374** 1
Bronchi-
olitisa 0.090 − 0.116 0.301** 1
Cavitationa 0.034 − 0.255* 0.320** 0.175 1
Nodulesa 0.068 − 0.171 0.059 0.151 − 0.001 1
Consolida-
tiona 0.284* − 0.275* 0.322** 0.431** 0.331** 0.072 1
Totala 0.154 − 0.358** 0.691** 0.630** 0.737** 0.191 0.618** 1
Serum 
CA19-9 0.171 − 0.043 0.251* 0.289** 0.221* 0.137 0.303** 0.416** 1
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normal limits) in patients with NTM-PD in this study, its utility as a diagnostic marker for NTM-PD was appar-
ently limited; however, it may be useful in assessing the severity of NTM-PD.
CA19-9 is the most commonly used serum marker for pancreatic cancer. CA19-9, which is synthesized by 
normal human pancreatic and biliary ductal cells and gastric, colonic, endometrial, and salivary epithelia, is pre-
sent in small amounts in serum, and may be elevated in several benign or malignant gastrointestinal  disorders30.
Moreover, increased CA19-9 levels have been observed in patients with several pulmonary  diseases31. Studies 
have shown that patients with idiopathic interstitial pneumonia (IIP)32, collagen disease-associated pulmonary 
 fibrosis33, diffuse panbronchiolitis (DPB)34, and  bronchiectasis31 had elevated serum CA19-9 levels.
The mechanism responsible for the elevation of serum CA19-9 in pulmonary diseases has not fully elucidated. 
However, previous studies using immunohistochemical staining reported that CA19-9 was selectively expressed 
in bronchiolar epithelial cells in patients with IIP and DPB, whereas alveolar epithelial cells or bronchiolar 
glandular cells were negative for CA19-9, irrespective of the  etiology32,34. Moreover, there was good correlation 
between the degree of inflammation and antigen expression and between the intensity of staining and antigen 
levels in bronchoalveolar lavage  fluid34. KL-6, which has been previously shown to be a potential biomarker of 
NTM-PD12, was also shown to be strongly expressed in bronchiolar epithelial  cells35. These findings indicate that 
Figure 2.  Scatter plot depicting the total CT score total and serum CA19-9 levels. CT computed tomography, 
CA carbohydrate antigen.
Table 5.  Partial correlation coefficient for CA19-9 and CT score for NTM-PD. CA carbohydrate antigen, CT 
computed tomography, NTM-PD nontuberculous mycobacterial pulmonary disease, CI confidence interval, 
BMI body mass index. a The controlled variables included age, sex and BMI.




Nodule 0.1450 (− 0.0155 to 0.2785)
Consolidation 0.3039 (0.1671–0.4122)
Total score 0.4162 (0.2846–0.5186)
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inflammation and damage to bronchiolar epithelial cells may be responsible for the elevation in serum CA19-9 
in chronic airway inflammatory diseases.
CT imaging indicates that small and large airways are the major sites of involvement in NTM-PD, which 
manifest with inflammatory bronchiolitis and bronchiectasis. Histopathologically, granulomatous inflammation 
of the airway walls is correlated with imaging  findings36. Although the assessment of the disease-specific activity 
and severity of NTM-PD is one of the most important factors in treating patients with NTM-PD, none of the 
known assessment tools are appropriate for NTM-PD. From the various clinical, radiological, and microbiologi-
cal assessments, radiographic examinations have played an essential role in the diagnosis of NTM-PD and also 
in determining the extent of the disease and assessing the response to treatment. CT imaging has considerably 
improved the assessment of this disease. Several scoring criteria have been devised for grading the disease sever-
ity of NTM-PD based on CT imaging. In the present study, the CT scores of the severity of lung involvement in 
NTM-PD were calculated using a modified version of a previously published scoring system proposed by Song 
et al.37 A previous study found that the scoring system was correlated with the results of the pulmonary function 
test and functional impairment in patients with MAC pulmonary disease and is also used to assess the treatment 
response of M. abscessus and M. massiliense pulmonary  disease28.
The prognostic value and effect of the extent of the disease or number of lung segments affected by NTM-PD 
on chest CT on the health-related quality of life of patients with NTM-PD have been  investigated38–41. Thus, the 
good correlation between serum CA19-9 levels and CT scores of patients with NTM-PD in our study suggests 
that serum CA19-9 levels may be used as a biomarker of the disease severity of NTM-PD.
Blood monitoring-based biomarkers, correlated with NTM-PD disease activity, may provide clinicians with 
reliable clues regarding the appropriate time to initiate treatment or information of treatment response during 
the course of treatment. Although some researchers have proposed a few biomarkers (i.e., anti-GPL  IgA11, type I 
cytokine-associated  molecules42, and KL-612) for assessing the response to therapy, they have not been validated 
sufficiently to be used in daily practice.
Hong et al.13 examined the clinical significance of CA19-9 as a biomarker for monitoring treatment for NTM-
PD. In that study, patients with good treatment response showed a significant decline in the CA19-9 level, while 
no difference was observed in the CA19-9 level between before and after treatment in non-responders.
Our study sought to reveal a direct correlation between serum CA19-9 and NTM-PD disease activity, which 
was reflected by the severity score based on chest CT imaging. We found a positive correlation between serum 
CA19-9 levels and the CT severity score for NTM-PD, which means that serum CA19-9 could be a potential 
biomarker for NTM-PD. Further studies are needed, especially those focusing on serial trends in serum CA19-9 
levels following disease progression or antimicrobial treatment.
Our study had a few limitations. First, we could not exclude patients with a negative Lewis antigen phenotype, 
because the Lewis antigen test was not performed routinely for all patients owing to the retrospective nature of the 
cohort study. Serum levels of CA19-9 are not elevated in patients with the Lewis negative  phenotype43. Therefore, 
there is a possibility of false-negative findings with respect to the serum CA19-9 levels in our study population, 
which means that the actual magnitude of the positive correlation may be greater. A study that evaluated blood 
samples from 225 healthy Korean volunteers found that 11.1% of participants exhibited the Lewis negative 
 phenotype44. Second, our study included a small sample with a retrospective study design, not including a control 
group. A group of participants with bronchiectasis without NTM-PD might be a good control. Third, we could 
not evaluate the effect of treatment, because serial measurements of serum CA19-9 levels were not available.
In conclusion, serum CA19-9 levels showed a positive correlation with the CT severity score for NTM-PD, 
especially the total score and subscores for bronchiectasis, bronchiolitis, cavitation, and consolidation. Serum 
CA19-9 may be a useful marker in evaluating disease activity or therapeutic response in patients with NTM-PD, 
and further studies on this topic are warranted.
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable 
request.
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